For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD joins Friends of Cancer Research and 50 other organizations in letter to the Senate supporting the nomination of Dr. Robert Califf to be Commissioner of the FDA
Published: Dec 1, 2021
Tagged in: Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science
NORD submits comments to FDA on draft guidance: Benefit-Risk Assessment for New Drug and Biological Products
Published: Nov 22, 2021
Tagged in: Advancing Rare Disease Research and Regulatory Science
NORD, MDA, and FARA letter to House and Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee on supporting rare disease programs at NCATS in FY22
Published: Nov 10, 2021
Tagged in: Appropriations, Ensuring Adequate Funding for NIH, Advancing Rare Disease Research and Regulatory Science
NORD comments on Prescription Drug User Fee Act VII Commitment Letter
Published: Oct 28, 2021
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
NORD and 86 other organizations oppose the Senate including changes to the Orphan Drug Tax Credit in the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Research, Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act, Orphan Drug Tax Credit
NORD and 86 other organizations ask for the removal of provisions related to the Orphan Drug Tax Credit in the House version of the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Research, Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act, Orphan Drug Tax Credit
